EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.